Arcutis Biotherapeutics Statistics
Total Valuation
ARQT has a market cap or net worth of $1.07 billion. The enterprise value is $874.23 million.
| Market Cap | 1.07B |
| Enterprise Value | 874.23M |
Important Dates
The last earnings date was Tuesday, May 14, 2024, after market close.
| Earnings Date | May 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
ARQT has 115.76 million shares outstanding. The number of shares has increased by 81.54% in one year.
| Shares Outstanding | 115.76M |
| Shares Change (YoY) | +81.54% |
| Shares Change (QoQ) | +60.23% |
| Owned by Insiders (%) | 2.11% |
| Owned by Institutions (%) | 109.17% |
| Float | 89.21M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 10.08 |
| Forward PS | 11.34 |
| PB Ratio | 4.77 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 8.22 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.89, with a Debt / Equity ratio of 0.92.
| Current Ratio | 9.89 |
| Quick Ratio | 9.34 |
| Debt / Equity | 0.92 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -6.10 |
Financial Efficiency
Return on equity (ROE) is -197.30% and return on invested capital (ROIC) is -45.51%.
| Return on Equity (ROE) | -197.30% |
| Return on Assets (ROA) | -60.70% |
| Return on Capital (ROIC) | -45.51% |
| Revenue Per Employee | $359,439 |
| Profits Per Employee | -$734,534 |
| Employee Count | 296 |
| Asset Turnover | 0.30 |
| Inventory Turnover | 0.68 |
Taxes
In the past 12 months, ARQT has paid $3.37 million in taxes.
| Income Tax | 3.37M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -8.09% in the last 52 weeks. The beta is 1.18, so ARQT's price volatility has been higher than the market average.
| Beta (1Y) | 1.18 |
| 52-Week Price Change | -8.09% |
| 50-Day Moving Average | 9.63 |
| 200-Day Moving Average | 6.35 |
| Relative Strength Index (RSI) | 54.20 |
| Average Volume (30 Days) | 3,809,587 |
Short Selling Information
The latest short interest is 21.69 million, so 18.74% of the outstanding shares have been sold short.
| Short Interest | 21.69M |
| Short Previous Month | 19.66M |
| Short % of Shares Out | 18.74% |
| Short % of Float | 24.31% |
| Short Ratio (days to cover) | 7.89 |
Income Statement
In the last 12 months, ARQT had revenue of $106.39 million and -$217.42 million in losses. Loss per share was -$2.80.
| Revenue | 106.39M |
| Gross Profit | 98.93M |
| Operating Income | -196.46M |
| Pretax Income | -214.05M |
| Net Income | -217.42M |
| EBITDA | -182.01M |
| EBIT | -183.90M |
| Loss Per Share | -$2.80 |
Balance Sheet
The company has $404.48 million in cash and $206.74 million in debt, giving a net cash position of $197.74 million or $1.71 per share.
| Cash & Cash Equivalents | 404.48M |
| Total Debt | 206.74M |
| Net Cash | 197.74M |
| Net Cash Per Share | $1.71 |
| Equity / Book Value | 224.94M |
| Book Value Per Share | 1.94 |
| Working Capital | 420.75M |
Cash Flow
In the last 12 months, operating cash flow was -$198.32 million and capital expenditures -$346,000, giving a free cash flow of -$198.66 million.
| Operating Cash Flow | -198.32M |
| Capital Expenditures | -346,000 |
| Free Cash Flow | -198.66M |
| FCF Per Share | -$1.79 |
Margins
Gross margin is 92.99%, with operating and profit margins of -184.65% and -204.36%.
| Gross Margin | 92.99% |
| Operating Margin | -184.65% |
| Pretax Margin | -201.19% |
| Profit Margin | -204.36% |
| EBITDA Margin | -171.08% |
| EBIT Margin | -172.85% |
| FCF Margin | -186.72% |
Dividends & Yields
ARQT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -81.54% |
| Shareholder Yield | -81.54% |
| Earnings Yield | -20.28% |
| FCF Yield | -18.53% |
Analyst Forecast
The average price target for ARQT is $28.14, which is 205.87% higher than the current price. The consensus rating is "Buy".
| Price Target | $28.14 |
| Price Target Difference | 205.87% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | 65.82% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ARQT has an Altman Z-Score of -0.43 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.43 |
| Piotroski F-Score | 3 |